Genetic instability and increased mutational load: Which diagnostic tool best direct patients with cancer to immunotherapy?

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Palmieri, Giuseppe ^a   Colombino, Maria ^a   Cossu, Antonio ^b   Marchetti, Antonio ^c   Botti, Gerardo ^d   Ascierto, Paolo A ^d  

^a CNR   (Italy)

^b UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DIAGNOSTIC TEST; DOWN REGULATION; EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; MUTATIONAL LOAD; NEXT GENERATION SEQUENCING; NOTE; PATIENT IDENTIFICATION; SOMATIC MUTATION; AGAR GEL ELECTROPHORESIS; GENE LOCUS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; NEOPLASM;

DNA; MICROSATELLITE DNA;

DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; GENETIC LOCI; GENOMIC INSTABILITY; HUMANS; IMMUNOTHERAPY; MICROSATELLITE REPEATS; MUTATION; NEOPLASMS;

EID: 85009999839     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-017-1119-6     Document Type: Note

References (28)

1. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-99.
2. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-8.
3. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.
4. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-11.
5. McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9.
6. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35-44.
7. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819-29.
8. Lengauer C, Kinzier KW, Volgestein B. Genetic instabilities in human cancers. Nature. 1998;396:643-9.
9. Sturzeneker R, Bevilacqua RA, Haddad LA, Simpson AJ, Pena SD. Microsatellite instability in tumors as a model to study the process of microsatellite mutations. Hum Mol Genet. 2000;9:347-52.
10. Richman S. Deficient mismatch repair: read all about it. Int J Oncol. 2015;47:1189-202.
11. Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21:1200-11.
12. Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;33:52810-7.
13. Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol. 2016;7:771-88.
14. Le DT, Uram JN, Wang H, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol. 2016;34 (abstr):195.
15. Sehdev A, Cramer HM, Ibrahim AA, Younger AE, O'Neil BH. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Discov Med. 2016;21:341-7.
16. Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16:30.
17. Chaves P, Cruz C, Lage P, et al. Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype. J Pathol. 2000;191:355-60.
18. Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014;23:246-57.
19. Goodfellow PJ, Billingsley CC, Lankes HA, et al. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch Syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol. 2015;33:4301-8.
20. Baldinu P, Cossu A, Manca A, et al. Microsatellite instability and mutation analysis of candidate genes in unselected Sardinian patients with endometrial cancer. Cancer. 2002;94:3157-68.
21. Colombino M, Cossu A, Manca A, et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol. 2002;13:1447-53.
22. Colombino M, Cossu A, Arba A, et al. Microsatellite instability and mutation analysis among Southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases. Ann Oncol. 2003;14:1530-6.
23. Strazzullo M, Cossu A, Baldinu P, et al. High-resolution methylation analysis of hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer. 2003;98:1540-6.
24. Colombino M, Cossu A, Budroni M, et al. Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma. Eur J Cancer. 2005;41:1058-64.
25. Leite M, Corso G, Sousa S, et al. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer. 2011;128:1606-13.
26. Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol. 2015;89:899-921.
27. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293-300.
28. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-8.